Table 1 Patients characteristics in our study cohort
From: The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas
Variable | Group 1 Oligodendroglioma, IDH-mutant and 1p19q–codeletion WHO grade II & III | Group 2 Anaplastic astrocytoma, IDH-mutant, WHO grade III | Group 3 Glioblastoma, IDH-mutant, WHO grade IV | Group 4 Anaplastic astrocytoma, IDH-wildtype, WHO grade III | Group 5 Glioblastoma IDH-wildtype WHO grade IV | |
|---|---|---|---|---|---|---|
No | n (%) | n (%) | n (%) | n (%) | n (%) | |
Number of Patients | 168 | 65 (100) | 23 (100) | 13 (100%) | 15 (100%) | 52 (100%) |
Age (years) | Mean (range) | 43.4 (21–65) | 42.6 (21–65) | 39 (29–49) | 48.6 (26–72) | 55.3 (27–79) |
Gender | Male | 33 (50.8) | 17 (73.9) | 9 (69.2) | 6 (40) | 35 (66.0) |
Female | 32 (49.2) | 6 (26.1) | 4 (30.8) | 9 (60) | 17 (34.0) | |
Mean OS (mo) | 38.0 (0–95) | 59.4 (0.5–114.8) | 40.0 (11.8–72.3) | 28.2 (0.5–76.9) | 19.6 (0.5–116) | |
Mean PFS (mo) | 38.0 (1–96) | 48.7 (0.5–114.8) | 36.0 (9.5–68.7) | 13.8 (0.5–76.9) | 15.4 (0–103) | |
TERT sequencing | Wildtype | 2 (3.1) | 22 (95.6) | 3 (23.1) | 12 (80) | 11 (21.2) |
Mutant | 63 (96.9) | 1 (4.4) | 10 (76.9) | 3 (20) | 41 78.8) | |
1p, 19q FISH | No co-deletion | 0 (0) | 0 (0) | 13 (100) | 15 (100) | 53 (100) |
Co-deletion | 65 (100) | 23 (100) | 0 (0) | 0 (0) | 0 (0) | |
ATRX IHC | Wildtype (retained) Mutant (loss) | 0 (0) 65 (100) | 7 (30.4) 16 (69.6) | 4 (30.7) 9 (69.2) | 9 (60) 6 (40) | 48 (92.3) 4 (7.7) |
MGMT MSP | No methylation | 11 (16.9) | 9 (39.1) | 3 (23.1) | 7 (46.7) | 26 (50.0) |
Methylation | 54 (83.1) | 14 (60.9) | 10 (76.9) | 8 (53.3) | 26 (50.0) | |
Ki-67 labeling index (%) | Mean (range) | 10.6 (1.5–39.5) | Not available | 14 (1–39.3) | Not available | 20.6 (0–54.8) |